Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial.

MLA

Cortes, Jorge E., et al. “Olutasidenib in Combination with Azacitidine Induces Durable Complete Remissions in Patients with Relapsed or Refractory MIDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial.” Journal of Hematology & Oncology, vol. 18, no. 1, Jan. 2025, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s13045-024-01657-z.

APA

Cortes, J. E., Roboz, G. J., Baer, M. R., Jonas, B. A., Schiller, G. J., Yee, K., Ferrell, P. B., Yang, J., Wang, E. S., Blum, W. G., Mims, A., Tian, H., Sheppard, A., de Botton, S., Montesinos, P., Curti, A., & Watts, J. M. (2025). Olutasidenib in combination with azacitidine induces durable complete remissions in patients with relapsed or refractory mIDH1 acute myeloid leukemia: a multicohort open-label phase 1/2 trial. Journal of Hematology & Oncology, 18(1), 1–13. https://doi.org/10.1186/s13045-024-01657-z

Chicago

Cortes, Jorge E., Gail J. Roboz, Maria R. Baer, Brian A. Jonas, Gary J. Schiller, Karen Yee, P. Brent Ferrell, et al. 2025. “Olutasidenib in Combination with Azacitidine Induces Durable Complete Remissions in Patients with Relapsed or Refractory MIDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial.” Journal of Hematology & Oncology 18 (1): 1–13. doi:10.1186/s13045-024-01657-z.